Risk predictors of early recurrence in women with epithelial ovarian cancer in Lagos, Nigeria

被引:9
作者
Okunade, Kehinde Sharafadeen [1 ,2 ]
Adetuyi, Imoleayo Elijah [2 ]
Adenekan, Muisi [2 ]
Ohazurike, Ephraim [2 ]
Anorlu, Rose Ihuoma [1 ,2 ]
机构
[1] Univ Lagos, Coll Med, Dept Obstet & Gynaecol, Lagos, Nigeria
[2] Lagos Univ Teaching Hosp, Dept Obstet & Gynaecol, Lagos, Nigeria
基金
美国国家卫生研究院;
关键词
Cytoreduction; epithelial ovarian cancer; FIGO stage; recurrence; Lagos; PACLITAXEL; SURVIVAL;
D O I
10.11604/pamj.2020.36.272.17827
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer with a recurrence rate as high as 85% after an initial treatment. However, there are currently no reliable means of predicting the risk of recurrence after first-line treatment. This study investigated the risk factors that predict early recurrence of EOC after primary treatment among women in Lagos, Nigeria. Methods: this was a retrospective cohort study involving the review of all histologically confirmed EOC patients managed at the Lagos University Teaching Hospital, Lagos, Nigeria over a 7-year period from January 2010 to December 2016. A study proforma was used to retrieve relevant information and descriptive statistics were computed for all data. The associations between variables were tested and multivariate analysis was done to adjust for all the possible characteristics that predict early EOC recurrence. Results: the rate of recurrence of EOC was 76.4%. Suboptimal debulking surgery is the only independent predictor of early tumour recurrence. Conclusion: women should be adequately counselled and encouraged to report their symptoms early to ensure optimal primary treatment. Strategic efforts should also be made to further improve subspecialty training programs and skills development in gynaecological oncology in Nigeria and sub-Saharan Africa.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 24 条
[1]   Ovarian Cancer Sites of Recurrence [J].
Amate, Pascale ;
Huchon, Cyrille ;
Dessapt, Anne Lucie ;
Bensaid, Cherazade ;
Medioni, Jacques ;
Belda, Marie-Aude Le Frere ;
Bats, Anne-Sophie ;
Lecuru, Fabrice R. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (09) :1590-1596
[2]  
Bray Freddie, 2018, CA Cancer J Clin, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]
[3]  
[Anonymous], 2005, NIG Q J HOSP MED
[4]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[5]   Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer [J].
Chang, Chung ;
Chiang, An Jen ;
Wang, Hui-Ching ;
Chen, Wei-An ;
Chen, Jiabin .
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (12) :3976-3980
[6]   Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment [J].
Craveiro, Vinicius ;
Yang-Hartwich, Yang ;
Holmberg, Jennie C. ;
Sumi, Natalia J. ;
Pizzonia, John ;
Griffin, Brian ;
Gill, Sabrina K. ;
Silasi, Dan-Arin ;
Azodi, Masoud ;
Rutherford, Thomas ;
Alvero, Ayesha B. ;
Mor, Gil .
CANCER MEDICINE, 2013, 2 (06) :751-762
[7]  
Gharoro E P, 2006, Afr J Med Med Sci, V35, P143
[8]  
Gil-Ibáñez B, 2011, ANTICANCER RES, V31, P2583
[9]   Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study [J].
Giorda, Giorgio ;
Gadducci, Angiolo ;
Lucia, Emilio ;
Sorio, Roberto ;
Bounous, Valentina E. ;
Sopracordevole, Francesco ;
Tinelli, Andrea ;
Baldassarre, Gustavo ;
Campagnutta, Elio .
JOURNAL OF OVARIAN RESEARCH, 2014, 7
[10]  
Iyoke C.A., 2013, World J Obstet Gynecol, V2, P1, DOI DOI 10.5317/WJOG.V2.I1.1